hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== Bibliography == J. Samuel Walker (November 1, 2000). Permissible Dose: A History of Radiation Protection in the Twentieth Century. University of California Press. ISBN 978-0-520-92484-0. Limited preview in Google Books. K. N. Govinda Rajan (July 28, 2017). Radiation Safety in Radiation Oncology. CRC Press. ISBN 978-1-4987-6226-7. Limited preview in Google Books. Strahlengefahrdung und Strahlenschutz / Radiation Exposure and Radiation Protection. Springer-Publisher. March 13, 2013. ISBN 978-3-642-82229-2. Limited preview in Google Books J. Samuel Walker (April 2001). Short History of Nuclear Regulation, 1946–1999. DIANE Publishing. ISBN 978-0-7567-0929-7.Limited preview in Google Books. Ashley W. Oughterson, Shields Warren: Medical Effects of the Atomic Bomb in Japan. Volume VIII.8 aus der National Nuclear Energy Series zum Manhattan Project, McGraw-Hill Book Company, 1956. Carl Voegtlin, Harold C. Hodge: Pharmacology and Toxicology of Uranium Compounds. Volume VI.1, Part I and Part II (with a Section on the Pharmacology and Toxicology of Fluorine and Hydrogen Fluoride) from the National Nuclear Energy Series to the Manhattan Project, McGraw-Hill Book Company, 1949. Henry DeWolf Smyth (written on the request of Maj. Gen. L. R. Groves): Atomic Energy for Military Purposes. The official report on the development of the atomic bomb under the auspices of the United States Government, 1940–1945. Princeton University Press, 1946. James E. Grindler (Argonne National Laboratory): The Radiochemistry of Uranium.
== Recognition by immune system == Peptidoglycan recognition is an evolutionarily conserved process. The overall structure is similar between bacterial species, but various modifications can increase the diversity. These include modifications of the length of sugar polymers, modifications in the sugar structures, variations in cross-linking or substitutions of amino acids (primarily at the third position). The aim of these modifications is to alter the properties of the cell wall, which plays a vital role in pathogenesis. Peptidoglycans can be degraded by several enzymes (lysozyme, glucosaminidase, endopeptidase...), producing immunostimulatory fragments (sometimes called muropeptides) that are critical for mediating host-pathogen interactions. These include muramyl dipeptide (MDP), N-acetylglucosamine (NAG), or γ-d-glutamyl-meso-diaminopimelic acid (iE-DAP). Peptidoglycan from intestinal bacteria (both pathogens and commensals) crosses the intestinal barrier even under physiological conditions. Mechanisms through which peptidoglycan or its fragments enter the host cells can be direct (carrier-independent) or indirect (carrier-dependent), and they are either bacteria-mediated (secretion systems, membrane vesicles) or host cell-mediated (receptor-mediated, peptide transporters). Bacterial secretion systems are protein complexes used for the delivery of virulence factors across the bacterial cell envelope to the exterior environment.
== Other applications == Decontamination: Prolidase from the hyperthermophilic archaeon Pyrococcus furiosus (Pfprol) shows potential for application in decontamination of organophosphorus nerve agents in chemical warfare agents. Additionally, prolidase could also serve to detect fluorine-containing organophosphorus neurotoxins, like the G-type chemical warfare agents, and could antagonize organophosphorous intoxication and protect against the effects of diisopropylfluorophosphate when encapsulated in liposomes.
==== Early career ==== Townsend joined the Tottenham Hotspur academy at the age of eight. In March 2009, he went on loan to Yeovil Town, making his football league debut against Milton Keynes Dons alongside fellow Spurs academy player Jonathan Obika. He made ten appearances and scored one goal for Yeovil as they avoided relegation.
Sources: en.wikipedia.org
In November 2023, the first global AI Safety Summit was held in Bletchley Park in the UK to discuss the near and far term risks of AI and the possibility of mandatory and voluntary regulatory frameworks. 28 countries including the United States, China, and the European Union issued a declaration at the start of the summit, calling for international co-operation to manage the challenges and risks of artificial intelligence. In May 2024 at the AI Seoul Summit, 16 global AI tech companies agreed to safety commitments on the development of AI. In March 2026, the United Nations convened the inaugural meeting of the Independent International Scientific Panel on AI, a 40-member expert body established under the Global Digital Compact to produce annual evidence-based reports on AI's societal impacts.
Chen, Li & Shi (2026) study the cranial morphology and phylogenetic affinities of Tossunnoria pseudibex, recover the species as a member of the bovid tribe Urmiatheriini, and interpret its caprin-like morphology as a result of convergent evolution. Revision of the type material of Pachygazella grangeri is published by Bai, Wang & Dong (2026). Evidence from the study of tooth wear of extant and Pleistocene springboks, indicative of variability of dietary signals in members of the same species both within and across different biomes, is presented by Walls et al. (2026). Dumitru et al. (2026) determine that deposition of fossils of Myotragus antiquus in Cova des Fum (Mallorca, Spain) happened between 3.60 and 3.45 million years ago, indicating that M. antiquus lived years earlier than indicated by previous estimates. Armaroli et al. (2026) provide new information on the late Pleistocene Alpine ibex population from Riparo Dalmeri (Italy) on the basis of the study of strontium, carbon and oxygen isotopic composition of their remains, ancient DNA data and radiocarbon dating, reporting evidence of stable density of the studied population despite intensive hunting and consistent human presence, as well as evidence dietary differences between sexes in the studied population. Sorbelli et al. (2026) describe fossil material of "Alephis" tigneresi from the Pliocene strata from Camp dels Ninots (Spain), and assign this species to the genus Parabos. Liang et al.
=== Trade === Crude oil is traded as a future on both the NYMEX and ICE exchanges. Futures contracts are agreements in which buyers and sellers agree to purchase and deliver specific amounts of physical crude oil on a given date in the future. A contract covers any multiple of 1,000 barrels and can be purchased up to nine years into the future.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.